Previous Article | Next Article ![]()
Journal of Virology, June 2007, p. 6339-6345, Vol. 81, No. 12
0022-538X/07/$08.00+0 doi:10.1128/JVI.00233-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Pathology/Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157,1 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461,2 Department of Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157,3 Departments of Pediatrics, Epidemiology & Population Health, and Obstetrics, Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, New York 104614
Received 2 February 2007/ Accepted 30 March 2007
|
|
|---|
|
|
|---|
The induction and development of CIN requires a very specific biologic context. PVs replicate only within a maturation lineage of keratinocytes, and high-risk HPVs generally target the basal epithelial cells of the cervical squamocolumnar junction (34). This cell type has a unique and variable phenotype (4) not easily reproduced in tissue culture systems. Host determinants such as hormone and immunologic status, coinfections, and environmental cofactors may also strongly influence viral persistence and oncogenic potential (3, 32). Collectively, these complex features of HPV-related oncogenesis have proven difficult to replicate in existing preclinical models of cervical neoplasia (2, 24).
The remarkable diversity of HPVs (with over 100 types now described) has not been reported in other animal species (8). This discrepancy is likely due in large part to survey bias but may also involve particular ecologic determinants of PV evolution. The high-risk oncogenic mucosal HPVs are members of the alpha-PV group, which collectively represents over half of the known HPV types (8). Related alpha-PVs have only been identified in other Old World primates, including macaques (6), colobus monkeys (20), and a pigmy chimpanzee (30). These reports are sporadic, however, and few studies have systematically evaluated and typed genital PVs across nonhuman primate populations (6, 22). In the most extensive survey, 12 novel rhesus PVs (RhPV-a through -m) and 1 cynomolgus PV (MfPV-a) were identified in genital samples from a group of 286 rhesus macaques (Macaca mulatta) and 7 cynomolgus macaques (Macaca fascicularis) (6), strongly suggesting that diverse lineages of genital alpha-PVs exist in different nonhuman primate species.
Among natural models of HPV-related disease, macaques are the only nonhuman species in which naturally occurring PV-associated cervical neoplasia has been described (21, 33). Survey studies of spontaneous cervical dysplasias in macaques were initially reported over three decades ago (9, 12, 13), although an association with PV infection was not established until more recently. In this initial report, PV DNA was identified in a metastasis of a primary penile carcinoma in a male rhesus macaque (21). A subsequent survey of 30 female macaques, some of which had known mating contact with the infected male, revealed DNA from this PV (named RhPV-1) from cervical samples in 19 of the females and dysplastic or invasive CINs in 6 of the females (21). More recently, we demonstrated that cervical neoplasia occurs relatively frequently in female macaques and that these lesions express PV antigens and share distinctive histopathologic similarities with those found in women (33). Molecular characterization of macaque PVs has been limited, however, and transmission has never been demonstrated experimentally. The goals of the current study were to characterize cervical lesions in relation to specific macaque PV types in a group of female cynomolgus macaques and to evaluate the experimental infectivity of a high-risk oncogenic macaque PV.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Survey of female cynomolgus macaques for PVsa
|
0.3 cm in diameter was used to collect exfoliated keratinocytes. A subset of the animals in study A (Table 1) were resampled 10 weeks (n = 13) and 31 weeks (n = 15) after the initial sampling. After collection, the brush was placed in a preservative solution (SurePath, Burlington, NC) and centrifuged to concentrate the cells. A portion of the cells were placed on a slide and Papanicolaou (Pap) stained for cytologic assessment using standard procedures. The remaining cell fraction was coded for laboratory blinding and frozen at –80°C before shipment for PV testing. Pap procedures were performed by the Cytopathology Laboratory at Wake Forest University NC Baptist Medical Center. PV DNA detection and typing. Cervicovaginal cell samples were screened for macaque PV DNA using PCR-based testing, as described previously for HPV detection (5, 11). Briefly, preserved cells were centrifuged and digested, and DNA was precipitated with ammonium acetate. Pelleted DNA was resuspended in Tris-EDTA buffer and amplified by PCR using gold Taq polymerase (Applied Biosystems, Foster City, CA) with MY09/11, GP5+/6+, and FAP primer sets targeting conserved regions of the L1 gene (1, 5, 10). PCR products of appropriate sizes were confirmed by agarose gel electrophoresis, purified by using the Quickstep2 PCR purification kit (Edge BioSystems, Gaithersburg, MD), and submitted for direct sequencing in the Einstein Sequencing Facility.
PCR products generated using monkey-specific primers (based on macaque PV L1 open reading frames [ORFs], available from investigators) were analyzed by gel electrophoresis, transferred to nylon filters, hybridized overnight with radiolabeled generic probes used for HPVs, washed at 55°C, and exposed to X-ray film (1). To analyze positive PCR products for their PV DNA type, aliquots of the initial PCR mixture were denatured and applied to replicate filters using a Hydra96 (Robbins Scientific). The filters were individually hybridized using biotinylated type-specific oligonucleotide probes for multiple known monkey PV types (6) and others identified on our initial analyses of sequence products, as described previously (5). Samples which tested positive by the generic probe mix but negative by all type-specific probes were classified as "uncharacterized" PV types. A subset of these PCR-positive and dot blot-negative samples were sequenced to confirm novel monkey PVs and to allow the development of additional dot blot probes. Hybridization signals were recorded using a 1+ to 5+ scale for signal intensity as a semiquantitative measure of type-specific viral load.
Macaque PV classification. Sequences of the MY09/11 region were compared with known PV sequences from the NCBI GenBank database using a BLAST searching algorithm. Viruses with MY09/11 DNA sequences less than 90% similar to previously typed PVs were numbered as novel MfPVs (8).
Tissue sampling and endoscopy.
To evaluate CIN prevalence by histology, cervical tissues were collected from the 54 survey animals either by biopsy (study A) or at necropsy (conducted for unrelated experimental reasons) (study B) (Table 1). For biopsy samples, animals were anesthetized with ketamine and butorphanol, and an endoscopy device (Stryker Endoscopy, Kalamazoo, MI) was used to remove a small pinch sample (
25 mg) of cervical mucosa. The endoscope was also used to record video footage of CIN lesions that were grossly evident. Prior to colposcopy, 1.0 ml of dilute acetic acid (5% solution) was applied to the cervix via pipette to assist in lesion visualization. Biopsies were performed by an experienced gynecologic surgeon (B. E. Miller). For collection of necropsy samples, the animals were first sedated with ketamine and then euthanized using sodium pentobarbital (100 mg/kg, intravenously), a method consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. All tissues were fixed at 4°C in 4% paraformaldehyde for 24 h, transferred to 70% ethanol, and then processed for histology by using standard procedures. Sections were stained with hematoxylin and eosin and reviewed by a board-certified veterinary pathologist (J. M. Cline). Lesions were scored using criteria adapted from the CIN nomenclature system, which uses the following categories (in order of increasing grade): CIN1, CIN2, CIN3 (carcinoma in situ), and invasive carcinoma (34). The association between PV and CIN status was evaluated by using a two-sided Fisher's exact test.
Immunohistochemistry. Immunohistochemical staining for markers of cell proliferation (Ki67) and PV infection (p16INK4a) was performed on fixed tissues. The following primary antibodies were used: Ki67 (MIB1; Dako, Carpinteria, CA) and p16INK4a (CMC811; Cell Marque, Hot Springs, AR). Biotinylated secondary Fc antibody was used as a linking reagent, and alkaline-phosphatase-conjugated streptavidin (Biogenex, San Ramon, CA) was applied for labeling. The chromogen used was Vector red, obtained as Vector red substrate kit no. 1 (Vector Laboratories, Burlingame, CA), diluted in Tris (pH 8.2 to 8.5) and applied to slides for 5 to 10 min at 30 to 35°C. Negative staining controls were obtained by omitting the primary antibody and substituting nonimmune serum (BioGenex, San Ramon, CA).
Experimental transmission of RhPV-d. A subset of animals (n = 13) from the survey study was used to evaluate the infectivity of RhPV-d. At 3-week intervals for 33 weeks, animals were sedated with ketamine and exfoliated cervicovaginal cells were transferred from the donor animal(s) to the 12 RhPV-d-negative animals. At weeks 0, 3, 6, and 9, cervical cells were transferred directly via cytobrush from a single donor animal (6660) to each recipient. At the 12-week time point, three RhPV-d-positive female macaques (6643, 6645, and 6646) from the original survey group were transferred into the inoculation study as donors in place of three RhPV-d-negative animals, and a new method of cervical cell transfer was adopted in which cervical cytobrush samples were collected from the four RhPV-d-positive donor animals (6660, 6643, 6645, and 6646), vortexed briefly in 1.5 ml of physiologic saline to remove cells from each brush, and centrifuged at 1,000 x g for 1 min. The supernatant was discarded, the pellets were resuspended by vortexing in 2.0 ml saline, and the donor samples were combined into a single inoculum. An aliquot of this inoculum (0.1 ml) was then applied via pipette directly to the cervixes of the nine recipients (weeks 15 to 33). Prior to each transfer, cytobrush samples were collected for cytology evaluation and viral DNA analysis.
Spliced E1^E4 RhPV-d transcripts. Exfoliated cervicovaginal cells collected by cytobrush at weeks 18 and 21 of the transmission study were resuspended in RNAlater RNA stabilization reagent (QIAGEN, Valencia, CA). Total RNAs were extracted by using an RNeasy mini kit (QIAGEN), treated with RNase-free DNase I (Promega, San Luis Obispo, CA), quantitated, and reverse transcribed using random hexamer primers (SuperScript first strand reverse transcription [RT]-PCR system; Invitrogen, Carlsbad, CA). PCR was performed by using a standard 45-cycle PCR thermocycling protocol with an equal mixture of AmpliTaq gold DNA (Applied Biosystems) and Pwo DNA polymerase (Gibco-BRL, Rockville, MD). The following primers were used to amplify a 180-bp RhPV-d-spliced E1^E4 fragment: 5' ACTGCAGCAGACCTCAATCC 3' (forward) and 5' CCTGTGGTGTTTTCACATGC 3' (reverse). Primers for macaque ß-actin (NCBI accession no. DQ464112) were also run as an internal mRNA control. PCR products were analyzed by gel electrophoresis and stained with ethidium bromide.
|
|
|---|
Evaluation of cervical neoplasia. Our next aim was to evaluate the relationships between specific macaque PV types and the presence of CIN, as determined by endoscopic visualization (colposcopy), cytology, and histology. In the survey study, evidence of CIN was identified by colposcopy in 7/15 animals, by histology in 6/54 animals, and by cytology in 8/54 animals (Table 2). Total lesion prevalence was 19% overall (10/54) and 53% (10/19) among PV-positive animals. All CIN lesions occurred among PV-positive animals (10/10), while no lesions were found in PV-negative animals (0/35) (P < 0.0001). Four different macaque PV types were associated with histologically confirmed CIN (RhPV-d, RhPV-a, MfPV-a, and MfPV novel type 3) (Table 2).
|
View this table: [in a new window] |
TABLE 2. Association between genital PV type and CIN in female cynomolgus macaques
|
![]() View larger version (136K): [in a new window] |
FIG. 1. Detection of naturally occurring CIN in female cynomolgus macaques. (A) Colposcopic features of CIN. Lesions showed increased vascularity, irregular cratering, and acetowhite staining of mucosa along the lesion margins (designated by arrows); the images are from animals with RhPV-d infections. (B) Cytologic features of CIN. Atypical Pap-stained keratinocytes had enlarged, irregular nuclei with increased chromatin staining; the cells are from animals with RhPV-d (upper) and MfPV-n3 (lower) infections. (C) Histologic features of CIN. The images show normal cervical mucosa with maturation strata of keratinocytes overlying a single layer of dark basal cells (left) and high-grade CIN lesions showing basal cell expansion, cellular atypia, nuclear enlargement, prominent nucleoli, and loss of polarity (middle, right); the lesions shown are from animals infected with RhPV-d. (D) Immunostaining for the proliferation marker Ki67 and the PV infection marker p16INK4a within normal cervical mucosa and CIN lesions (left and right, respectively).
|
![]() View larger version (47K): [in a new window] |
FIG. 2. Characterization and experimental transmission of RhPV-d in female macaques. (A) Phylogenetic classification of the RhPV-d genome, showing close relationships to RhPV-1 and HPV16. CgPV, colobus monkey PV; PCPV, pygmy chimpanzee PV. (B) CIN associated with experimental RhPV-d infection in animal 6656. Atypical cervical cells were found by Pap cytology (left) after 18 weeks of RhPV-d infection, and dysplasia was seen in a cervical biopsy taken after 27 weeks of infection, shown here immunostained for proliferation marker Ki67 and PV infection marker p16INK4a. (C) Detection of spliced RhPV-d E1^E4 mRNA in female macaques by RT-PCR at week 21 of transmission study. Black arrows indicate positive samples from donor animals (6660 and 6646). Dark gray arrows indicate positive samples from three recipient animals (6654, 6656, and 6636). Interestingly, animal 6636 tested positive for RhPV-d E1^E4 mRNA but not DNA. Light gray arrows indicate samples from the other donor animals, 6643 and 6645 (inconclusive). Note also that animal 6644, which tested positive for MfPV-n3, did not test positive for the RhPV-d E1^E4 gene target. Molecular weight markers are shown on the left. ß-Actin was used as an internal mRNA control. (D) Sequence analysis of RhPV-d MY09/11 fragments amplified from cervical cell DNA samples from two donors (d) (6660 and 6646); four recipients (r) at week 12 (6656 and 6644), week 21 (6636), and week 24 (6654); and a separate RhPV-d-positive animal (7312) from the initial survey. The RhPV-d reference sequence (ref) was obtained from GenBank (6). Note that the vertical numbers above the sequences represent only the nucleotide positions that varied (7), so the horizontal nucleotide sequences shown in the lower portion are not contiguous.
|
|
View this table: [in a new window] |
TABLE 3. Experimental transmission of RhPV-d in female macaquesa
|
|
|
|---|
Species specificity is considered a hallmark of PV biology. Apart from certain cutaneous bovine PVs (which have been isolated from horses and other hooved mammals), PVs are not considered to be infective across host species (2). In this study of cynomolgus macaques, we identified two genital PVs previously reported in a colony of rhesus macaques (6). Rhesus and cynomolgus macaques have only
0.4% divergence in their coding region sequences, compared to
2.2% average divergence between macaque and human coding sequences (15); still, the apparent cross-infectivity of RhPV-d and RhPV-a in separate macaque species is an unexpected finding and suggests that certain molecular boundaries restricting cross-species infectivity of primate genital PVs may be only partial in some instances. Future studies of macaque PV diversity and epidemiology should help identify these molecular barriers, as well as other determinants of viral host specificity.
Vaccines targeting particular types of oncogenic genital HPVs have been shown recently to be safe and effective in preventing persistent HPV infection and CIN lesions in young women (16, 31), representing a major landmark in cancer prevention. Nevertheless, important questions about prophylactic HPV vaccines remain, such as duration of protection, type specificity of the antibody responses, age dependence of protection, and efficacy following prior HPV exposure. Current vaccines are not effective for treatment of active HPV infections or CIN lesions, and the anticipated expense may limit their use in less-developed countries where cervical cancer is most common (25). A nonhuman primate model of PV infection and cervical neoplasia may be valuable in the development/refinement of second-generation vaccines and other antiviral therapeutics that address these limitations.
The development of a suitable animal model for cervical cancer has been a challenging problem in women's health research for many years. Current tissue culture, transgenic mouse, and natural PV infection models have led to considerable advances in our understanding of PV pathobiology (24). However, key differences between these systems and natural HPV infections (e.g., in microenvironment, mucosal tropism, viral transcription, and genomic factors) have limited their use in addressing certain important questions of HPV persistence and oncogenesis (2, 24). The findings of this study suggest that female macaques may serve as a unique and highly relevant preclinical model for the study of PV biology and CIN pathogenesis. Such a model would provide an important research resource for evaluating preventive and therapeutic strategies against HPV-related disease.
This work was supported in part by Public Health Service award K01 RR21322-02 from the National Center for Research Resources (NCRR), National Institutes of Health (NIH), and by GlaxoSmithKline (GSK).
The contents of this work are solely the responsibility of the authors and do not necessarily represent the view of the NCRR, NIH, or GSK.
Published ahead of print on 11 April 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»